Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity

By LabMedica International staff writers
Posted on 20 Jul 2026

Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations. More...

The disease can progress to acute myeloid leukemia, highlighting the need for objective, reproducible risk measures. Conventional histopathology and genetic testing can also leave a diagnostic gray zone. New findings demonstrate an artificial intelligence approach that turns routine marrow images into a quantitative disease score.

Weill Cornell Medicine investigators developed the MDS-Microarchitectural Perturbation Score (MDS-MAPS), an artificial intelligence (AI) method that quantifies disease severity in bone marrow biopsies from patients with myelodysplastic neoplasms (MDS). The approach compares the spatial positions and morphometric characteristics of every hematopoietic cell in a patient sample with those in healthy marrow to generate a single score. It analyzes digital images produced through routine staining and imaging workflows commonly available in hospital pathology laboratories.

MDS-MAPS ranks samples using 82 features associated with normal tissue and genetic MDS subtypes. The investigators used fully deidentified patient samples and indicate that the score can be generated at diagnosis and tracked longitudinally. Lower scores resemble healthy tissue, while higher scores reflect greater disease-related architectural disruption.

In computer modeling, the tool classified disease status more accurately than current assessment methods. Beyond scoring, the study found that healthy bone marrow follows a conserved architecture and that stem cells become increasingly misplaced as MDS advances. Reduced expression of the CXCR4 receptor was observed in stem cells from patients, particularly when TP53 mutations were present, offering insights that could further refine pathology monitoring.

The work was published June 30 in Leukemia. The team plans to validate the approach in larger cohorts and evaluate it in additional MDS forms and increasingly recognized precursor conditions.

“Using AI to assist us in looking at the spatial architecture of the bone marrow using widely available laboratory assays allows us to improve our capability to assess patients’ prognosis and perhaps triage them for precision therapies,” said Dr. David Redmond, assistant professor of computational biology research in medicine at Weill Cornell Medicine.

“We can generate an MDS-MAPS value for a patient at diagnosis and track how it changes over time,” said Dr. Sanjay Patel, clinical chief of hematopathology and associate professor of pathology and laboratory medicine at Weill Cornell Medicine. “It distills something very complex down into a numerical value. It is easier for a patient to understand whether their score is trending in the right or wrong direction, or whether their disease is more likely stable.” 

Related Links
Weill Cornell Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.